Phase IIIB-IV long term follow-up study for patients who participated in CAMMS03409

Phase 1

• Conditions: Relapsing-remitting multiple sclerosis; MedDRA version: 17.0Level: PTClassification code 10063399Term: Relapsing-remitting multiple sclerosisSystem Organ Class: 10029205 - Nervous system disorders; Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

• Registration Number: EUCTR2013-003884-71-ES
• Lead Sponsor: Genzyme Corporation

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2014-10-03
• Study Completion: 2020-07-15
• Last Update Posted: 19 April 2022

Recruitment & Eligibility

• Status: ot Recruiting
• Sex: All
• Target Recruitment: 1062

Inclusion Criteria

- Patient has completed at least 48 months of the Extension Study CAMMS03409
- Signed written informed consent form
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 799
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

- Patient participating in another investigational interventional study

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified